Supplemental Figure 2. Stability of PBMC cytotoxicity in healthy, untreated beagles over time. Beagle PBMC cytotoxicity against the canine (A) OSA target line (OSCA-78) cell line at 1:1 and 20:1 effector-to-target ratios and (B) melanoma (M5) cell line at 1:1 effector-to-target ratio showed no significant differences over multiple time points from the same donor (SYQ-5) in a schedule similar to inhaled IL-15 clinical trial. Donor beagle (XIO-6) PBMC cytotoxicity against the (C) OSCA-78 at 1:1 and 20:1 effector-to-target and (D) M5 cell lines at a 1:1 effector-to-target ratio. These experiments were repeated 3 times total.